Do analysts recommend ISPC or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ISPC or VIVS?

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iSpecimen $1.93M 1.20 -$10.49M -$56.44 N/A VivoSim Labs $130K 20.02 -$13.84M -$4.47 N/A

Is ISPC or VIVS more profitable?

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -524.39% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% VivoSim Labs -11,016.07% -612.23% -177.02%

Does the media favor ISPC or VIVS?

In the previous week, iSpecimen and iSpecimen both had 1 articles in the media. VivoSim Labs' average media sentiment score of 0.89 beat iSpecimen's score of 0.87 indicating that VivoSim Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iSpecimen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BFRGW or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BFRGW or ISPC?

Bullfrog AI has higher earnings, but lower revenue than iSpecimen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bullfrog AI $298.80K N/A N/A N/A N/A iSpecimen $1.93M 1.20 -$10.49M -$56.44 N/A

Is BFRGW or ISPC more profitable?

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A N/A N/A iSpecimen -2,445.40% -524.39% -140.42%

Does the media prefer BFRGW or ISPC?

In the previous week, Bullfrog AI and Bullfrog AI both had 1 articles in the media. iSpecimen's average media sentiment score of 0.87 beat Bullfrog AI's score of 0.60 indicating that iSpecimen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bullfrog AI 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iSpecimen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate OABIW or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, OABIW or ISPC?

OmniAb has higher revenue and earnings than iSpecimen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $38.46M N/A N/A N/A N/A iSpecimen $1.93M 1.20 -$10.49M -$56.44 N/A

Is OABIW or ISPC more profitable?

OmniAb has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. OmniAb's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb N/A N/A N/A iSpecimen -2,445.40% -524.39% -140.42%

Do analysts rate ISPC or TBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ISPC or TBIO more profitable?

Telesis Bio has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Telesis Bio's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% Telesis Bio N/A N/A N/A

Do analysts prefer ISPC or TMO?

Thermo Fisher Scientific has a consensus target price of $654.05, suggesting a potential downside of 5.24%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Thermo Fisher Scientific is more favorable than iSpecimen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Thermo Fisher Scientific 2 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 2 Strong Buy rating(s) 2.81

Does the media prefer ISPC or TMO?

In the previous week, Thermo Fisher Scientific had 31 more articles in the media than iSpecimen. MarketBeat recorded 32 mentions for Thermo Fisher Scientific and 1 mentions for iSpecimen. Thermo Fisher Scientific's average media sentiment score of 1.03 beat iSpecimen's score of 0.87 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iSpecimen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Thermo Fisher Scientific 22 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

iSpecimen (ISPC) Competitors

$0.92 -0.11 (-10.97%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$0.94 +0.02 (+2.29%)

As of 10/16/2026 07:01 PM Eastern

Compare

ISPC vs. VIVS, BFRGW, OABIW, TBIO, and TMO

Should you buy iSpecimen stock or one of its competitors? iSpecimen's main competitors and comparable companies include VivoSim Labs (VIVS), Bullfrog AI (BFRGW), OmniAb (OABIW), Telesis Bio (TBIO), and Thermo Fisher Scientific (TMO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does iSpecimen compare to VivoSim Labs?

iSpecimen (NASDAQ:ISPC) and VivoSim Labs (NASDAQ:VIVS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -524.39% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

13.6% of iSpecimen shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 12.2% of iSpecimen shares are held by company insiders. Comparatively, 1.0% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.20	-$10.49M	-$56.44	N/A
VivoSim Labs	$130K	20.02	-$13.84M	-$4.47	N/A

In the previous week, iSpecimen and iSpecimen both had 1 articles in the media. VivoSim Labs' average media sentiment score of 0.89 beat iSpecimen's score of 0.87 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iSpecimen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iSpecimen has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Summary

iSpecimen beats VivoSim Labs on 8 of the 11 factors compared between the two stocks.

How does iSpecimen compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRGW) and iSpecimen (NASDAQ:ISPC) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, Bullfrog AI and Bullfrog AI both had 1 articles in the media. iSpecimen's average media sentiment score of 0.87 beat Bullfrog AI's score of 0.60 indicating that iSpecimen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bullfrog AI	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iSpecimen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bullfrog AI has higher earnings, but lower revenue than iSpecimen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$298.80K	N/A	N/A	N/A	N/A
iSpecimen	$1.93M	1.20	-$10.49M	-$56.44	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	N/A	N/A
iSpecimen	-2,445.40%	-524.39%	-140.42%

13.6% of iSpecimen shares are held by institutional investors. 12.2% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

iSpecimen beats Bullfrog AI on 5 of the 8 factors compared between the two stocks.

How does iSpecimen compare to OmniAb?

OmniAb (NASDAQ:OABIW) and iSpecimen (NASDAQ:ISPC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

In the previous week, iSpecimen had 1 more articles in the media than OmniAb. MarketBeat recorded 1 mentions for iSpecimen and 0 mentions for OmniAb. OmniAb's average media sentiment score of 1.79 beat iSpecimen's score of 0.87 indicating that OmniAb is being referred to more favorably in the media.

Company	Overall Sentiment
OmniAb	Very Positive
iSpecimen	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

OmniAb has higher revenue and earnings than iSpecimen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	N/A	N/A	N/A	N/A
iSpecimen	$1.93M	1.20	-$10.49M	-$56.44	N/A

OmniAb has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. OmniAb's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
iSpecimen	-2,445.40%	-524.39%	-140.42%

Summary

OmniAb beats iSpecimen on 5 of the 9 factors compared between the two stocks.

How does iSpecimen compare to Telesis Bio?

iSpecimen (NASDAQ:ISPC) and Telesis Bio (OTCMKTS:TBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

iSpecimen has higher earnings, but lower revenue than Telesis Bio. iSpecimen is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.20	-$10.49M	-$56.44	N/A
Telesis Bio	$27.51M	0.00	-$47.72M	-$20.52	N/A

iSpecimen has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.58, suggesting that its share price is 158% more volatile than the broader market.

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 37.6% of Telesis Bio shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by company insiders. Comparatively, 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Telesis Bio has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Telesis Bio's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
Telesis Bio	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, iSpecimen had 1 more articles in the media than Telesis Bio. MarketBeat recorded 1 mentions for iSpecimen and 0 mentions for Telesis Bio. iSpecimen's average media sentiment score of 0.87 beat Telesis Bio's score of 0.00 indicating that iSpecimen is being referred to more favorably in the media.

Company	Overall Sentiment
iSpecimen	Positive
Telesis Bio	Neutral

Summary

Telesis Bio beats iSpecimen on 8 of the 13 factors compared between the two stocks.

How does iSpecimen compare to Thermo Fisher Scientific?

iSpecimen (NASDAQ:ISPC) and Thermo Fisher Scientific (NYSE:TMO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Thermo Fisher Scientific has a consensus target price of $654.05, suggesting a potential downside of 5.24%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Thermo Fisher Scientific is more favorable than iSpecimen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Thermo Fisher Scientific	2 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.81

Thermo Fisher Scientific has a net margin of 15.04% compared to iSpecimen's net margin of -2,445.40%. Thermo Fisher Scientific's return on equity of 17.09% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
Thermo Fisher Scientific	15.04%	17.09%	8.12%

In the previous week, Thermo Fisher Scientific had 31 more articles in the media than iSpecimen. MarketBeat recorded 32 mentions for Thermo Fisher Scientific and 1 mentions for iSpecimen. Thermo Fisher Scientific's average media sentiment score of 1.03 beat iSpecimen's score of 0.87 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iSpecimen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	22 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by company insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Thermo Fisher Scientific has higher revenue and earnings than iSpecimen. iSpecimen is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.20	-$10.49M	-$56.44	N/A
Thermo Fisher Scientific	$44.56B	5.73	$6.70B	$18.59	37.13

iSpecimen has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Summary

Thermo Fisher Scientific beats iSpecimen on 15 of the 17 factors compared between the two stocks.

Get iSpecimen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ISPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ISPC vs. The Competition

Export

Metric	iSpecimen	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.59M	$10.92B	$7.44B	$12.94B
Dividend Yield	N/A	1.45%	2.50%	27.63%
P/E Ratio	-0.02	18.26	198.80	19.05
Price / Sales	1.20	102.44	569.18	76.54
Price / Cash	N/A	27.39	76.54	51.88
Price / Book	0.06	5.88	10.29	5.85
Net Income	-$10.49M	$56.67B	$3.50B	$380.67M
7 Day Performance	-18.85%	-4.32%	-5.38%	-5.00%
1 Month Performance	-32.07%	-0.06%	-9.56%	-7.94%
1 Year Performance	-96.91%	21.37%	0.84%	-5.63%

iSpecimen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ISPC iSpecimen	0.8631 of 5 stars	$0.92 -11.0%	N/A	-97.2%	$2.59M	$1.93M	N/A	7	News Coverage Analyst Downgrade
VIVS VivoSim Labs	0.7328 of 5 stars	$0.20 -2.2%	N/A	-94.0%	$3.42M	$130K	N/A	11	Gap Up
BFRGW Bullfrog AI	N/A	$0.14 +21.4%	N/A	-75.5%	$0.00	$298.80K	N/A	9	Gap Down
OABIW OmniAb	N/A	$0.30 -22.1%	N/A	+81.0%	$0.00	$38.46M	N/A	89	Gap Down
TBIO Telesis Bio	N/A	N/A	N/A	N/A	$0.00	$225.09M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ISPC) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iSpecimen (ISPC) Competitors

ISPC vs. VIVS, BFRGW, OABIW, TBIO, and TMO

How does iSpecimen compare to VivoSim Labs?

Summary

How does iSpecimen compare to Bullfrog AI?

Summary

How does iSpecimen compare to OmniAb?

Summary

How does iSpecimen compare to Telesis Bio?

Summary

How does iSpecimen compare to Thermo Fisher Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ISPC vs. The Competition

iSpecimen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iSpecimen (ISPC) Competitors

ISPC vs. VIVS, BFRGW, OABIW, TBIO, and TMO

How does iSpecimen compare to VivoSim Labs?

Do analysts recommend ISPC or VIVS?

Is ISPC or VIVS more profitable?

Do insiders and institutionals have more ownership in ISPC or VIVS?

Which has better earnings & valuation, ISPC or VIVS?

Does the media favor ISPC or VIVS?

Which has more volatility and risk, ISPC or VIVS?

Summary

How does iSpecimen compare to Bullfrog AI?

Does the media prefer BFRGW or ISPC?

Which has stronger earnings and valuation, BFRGW or ISPC?

Do analysts rate BFRGW or ISPC?

Is BFRGW or ISPC more profitable?

Do insiders & institutionals believe in BFRGW or ISPC?

Summary

How does iSpecimen compare to OmniAb?

Does the media favor OABIW or ISPC?

Do insiders & institutionals hold more shares of OABIW or ISPC?

Do analysts rate OABIW or ISPC?

Which has stronger earnings & valuation, OABIW or ISPC?

Is OABIW or ISPC more profitable?

Summary

How does iSpecimen compare to Telesis Bio?

Which has higher valuation & earnings, ISPC or TBIO?

Which has more volatility and risk, ISPC or TBIO?

Do institutionals & insiders have more ownership in ISPC or TBIO?

Is ISPC or TBIO more profitable?

Do analysts rate ISPC or TBIO?

Does the media prefer ISPC or TBIO?

Summary

How does iSpecimen compare to Thermo Fisher Scientific?

Do analysts prefer ISPC or TMO?

Is ISPC or TMO more profitable?

Does the media prefer ISPC or TMO?

Do insiders & institutionals hold more shares of ISPC or TMO?

Which has stronger valuation and earnings, ISPC or TMO?

Which has more risk & volatility, ISPC or TMO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ISPC vs. The Competition

iSpecimen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools